Skip to content

Comparison of Hemodynamic Changes between High-Flow Nasal Oxygen Therapy and Face Mask Ventilation

Comparison of Hemodynamic Changes between High-Flow Nasal Oxygen Therapy and Face Mask Ventilation during Remimazolam Induction in Elderly Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1032250187
Enrollment
60
Registered
2025-06-26
Start date
2025-06-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing surgery under general anesthesia General Anesthesia

Interventions

None listed

Sponsors

Asai Takashi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled to undergo surgery under general anesthesia Patients scheduled to receive remimazolam as a sedative agent for anesthesia induction Patients aged 70 years or older at the time of consent acquisition Patients classified as American Society of Anesthesiologists (ASA) Physical Status Class 1 to 3 Class 1 A normal healthy patient without organic, physiological, biochemical, or psychiatric disturbances. The surgical condition is localized and does not cause systemic disturbance. Class 2 A patient with mild to moderate systemic disease, either due to the condition requiring surgery or other pathophysiological causes. Class 3 A patient with severe systemic disease, regardless of the underlying cause or whether the degree of dysfunction can be precisely determined. Patients who have provided informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Patients undergoing emergency surgery 2.Patients undergoing cardiac surgery 3.Patients who may be pregnant 4.Patients with a predicted difficult airway or anticipated difficult intubation 5.Patients with a body mass index (BMI) of 35 or higher 6.Patients considered to be at high risk of aspiration 7.Patients with conditions in which carbon dioxide retention is undesirable (e.g., pulmonary hypertension, right heart failure) 8.Patients with a history of ischemic heart disease or heart failure 9.Patients receiving dialysis

Design outcomes

Primary

MeasureTime frame
Incidence of hypotension (defined as a mean arterial pressure < 65 mmHg at the point of greatest blood pressure decrease)

Secondary

MeasureTime frame
Total dose of vasopressors administered during anesthesia induction Incidence of hypoxemia (defined as a lowest oxygen saturation < 95%)

Countries

Japan, nonen

Contacts

Public ContactRyosuke Osawa

Dokkyo Medical U niversity Saitama Medical Center

r-oosawa@dokkyomed.ac.jp+81-48-965-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026